MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
The Lancet Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

832 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
832 works in the cohort · of 4,299,418page 1 of 17

Labels cover 9 of 832 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 832 of 832 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki, Gregory A. Masters, George Blumenschein, Steven E. Schild +16 more
2015· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
2,007
citations
affno abstractunlabeled
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag, Stewart Anderson, Thomas B. Julian, Ann Brown, Seth P. Harlow, Joseph P. Costantino +9 more
2010· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
1,919
citations
affno abstractunlabeled
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda +12 more
2016· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,822
citations
affno abstractunlabeled
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter +14 more
2019· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,681
citations
affno abstractunlabeled
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain, William E. Barlow, Steven Shak, Gabriel N. Hortobágyi, Robert B. Livingston, I‐Tien Yeh +16 more
2009· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
1,405
citations
affno abstractunlabeled
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders, Cora N. Sternberg +19 more
2015· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,354
citations
affno abstractunlabeled
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi, Ryan Woods, Peter M. Ravdin, Malcolm Hayes, Karen A. Gelmon
2010· review· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
1,226
citations
affno abstractunlabeled
Expanding global access to radiotherapy
Rifat Atun, David A. Jaffray, Michael Bartoň, Freddie Bray, Michaël Baumann, Bhadrasain Vikram +12 more
2015· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,085
citations
affno abstractunlabeled
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero +13 more
2015· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
955
citations
next →

How this was built: Screen · Findings · About